Results 11 to 20 of about 24,793 (292)

Chlorambucil and fludarabine as a new pre-transplant conditioning for patients with chronic lymphocytic leukemia: results of in vivo experiments [PDF]

Veterinární Medicína, 2008
Chronic lymphatic leukemia (CLL), incurable by standard treatments, may be potentially cured by allogeneic hematopoietic stem cell transplantation. Since CLL affects predominantly older people, there is a need for some low-toxicity conditioning with, on ...
J. Tomenendalova, J. Mayer, M. Doubek, D. Horky, K. Rehakova, J. Doubek   +5 more
doaj   +2 more sources

Successful outcome after a single endoscopic fecal microbiota transplantation in a Shiba dog with non-responsive enteropathy during the treatment with chlorambucil

Journal of Veterinary Medical Science, 2021
A 7-year 6-month-old, castrated male Shiba dog presented with a 1-month history of lethargy, anorexia, vomiting, and frequent watery diarrhea. Weight loss, hypoalbuminemia, anemia, and leukocytosis were detected at the first visit.
Koji Sugita, A. Shima, Kaho Takahashi, Yasuyoshi Matsuda, Masaki Miyajima, Marin Hirokawa, H. Kondo, J. Kimura, Genki Ishihara, K. Ohmori   +9 more
semanticscholar   +3 more sources

Chlorambucil Conjugated Ugi Dendrimers with PAMAM-NH₂ Core and Evaluation of Their Anticancer Activity

Pharmaceutics, 2019
Herein, a new Ugi multicomponent reaction strategy is described to enhance activity and solubility of the chemotherapeutic drug chlorambucil through its conjugation to poly(amidoamine) (PAMAM-NH2) dendrimers with the simultaneous introduction of lipidic (
Nalin Seixas, Bruno B. Ravanello, Ibrahim Morgan, Goran N. Kaluđerović, Ludger A. Wessjohann   +4 more
doaj   +2 more sources

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2 [PDF]

Haematologica, 2018
Results of RESONATE-2 (PCYC-1115/1116) supported approval of ibrutinib for first-line treatment of chronic lymphocytic leukemia. Extended analysis of RESONATE-2 was conducted to determine long-term efficacy and safety of ibrutinib in older patients with ...
Paul M. Barr, Tadeusz Robak, Carolyn Owen, Alessandra Tedeschi, Osnat Bairey, Nancy L. Bartlett, Jan A. Burger, Peter Hillmen, Steven Coutre, Stephen Devereux, Sebastian Grosicki, Helen McCarthy, Jianyong Li, David Simpson, Fritz Offner, Carol Moreno, Cathy Zhou, Lori Styles, Danelle James, Thomas J. Kipps, Paolo Ghia   +20 more
doaj   +10 more sources

Synthesis, Characterization, and Cytotoxicity Evaluation of Chlorambucil-Functionalized Mesoporous Silica Nanoparticles [PDF]

Pharmaceutics
This study describes the synthesis and characterization of chlorambucil (CLB)-functionalized mesoporous silica nanoparticles (MSNs) for potential application in cancer therapy.
Juliana Camila Fischer Karnopp, Juliana Jorge, Jaqueline Rodrigues da Silva, Diego Boldo, Kristiane Fanti Del Pino Santos, Adriana Pereira Duarte, Gustavo Rocha de Castro, Ricardo Bentes de Azevedo, Ariadna Lafourcade Prada, Jesús Rafael Rodríguez Amado, Marco Antonio Utrera Martines   +10 more
doaj   +2 more sources

Retrospective Safety Evaluation of Combined Chlorambucil and Toceranib for the Treatment of Different Solid Tumours in Dogs [PDF]

Animals
Chlorambucil is used in veterinary medicine for various cancers, while Toceranib, which was licenced for treating canine mast cell tumours, is now used against other solid tumours.
Yuk-Yin Lai, Rodrigo Dos Santos Horta, Paola Valenti, Antonio Giuliano   +3 more
doaj   +2 more sources

Therapeutic effect of F127-folate@PLGA/CHL/IR780 nanoparticles on folate receptor-expressing cancer cells [PDF]

Beilstein Journal of Nanotechnology
Theragnostic platforms, which integrate therapeutic and diagnostic capabilities, have gained significant interest in drug research because of to their potential advantages.
Thi Ngoc Han Pham, Phuong-Thao Dang-Luong, Hong-Phuc Nguyen, Loc Le-Tuan, Xuan Thang Cao, Thanh-Danh Nguyen, Vy Tran Anh, Hieu Vu_Quang   +7 more
doaj   +2 more sources

Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison [PDF]

Advances in Therapy, 2017
IntroductionIbrutinib (ibr) monotherapy and the combination of obinutuzumab plus chlorambucil (obi) are approved for previously untreated chronic lymphocytic leukemia (CLL). No trials directly comparing their efficacy are available.
S. Van Sanden, S. Baculea, J. Diels, S. Côté   +3 more
semanticscholar   +2 more sources

Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis

ClinicoEconomics and Outcomes Research, 2014
Thitima Kongnakorn,1 James A Sterchele,2 Christopher G Salvador,3 Denis Getsios,4 Mkaya Mwamburi51Evidera, Bangkok, Thailand; 2formerly of Teva Branded Pharmaceutical Products R&D, Inc, Frazer, PA, 3Oncology Market Research, Teva Branded ...
Kongnakorn T, Sterchele JA, Salvador CG, Getsios D, Mwamburi M   +4 more
doaj   +3 more sources

Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN

Blood, 2023
Background: Previous reports of ELEVATE-TN (NCT02475681) at median follow-up of up to 58.2 months (mo) demonstrated superior efficacy of acalabrutinib (A) ± obinutuzumab (O) compared with O + chlorambucil (Clb) in patients (pts) with treatment-naive ...
J. Sharman, M. Egyed, Wojciech Jurczak, A. Skarbnik, K. Patel, I. Flinn, M. Kamdar, T. Munir, R. Walewska, Marie Hughes, L. Fogliatto, Y. Herishanu, V. Banerji, G. Follows, Patricia A. Walker, Karin Karlsson, P. Ghia, A. Janssens, F. Cymbalista, John C. Byrd, E. Ferrant, A. Ferrajoli, W. Wierda, V. Munugalavadla, Catherine Wangui Wachira, Chuan-Chaun Wun, J. Woyach   +26 more
semanticscholar   +1 more source